EPIGENOMICS N Helden (Seite 311)
eröffnet am 24.08.06 16:40:24 von
neuester Beitrag 13.05.24 22:20:26 von
neuester Beitrag 13.05.24 22:20:26 von
Beiträge: 52.370
ID: 1.078.825
ID: 1.078.825
Aufrufe heute: 13
Gesamt: 8.315.308
Gesamt: 8.315.308
Aktive User: 0
ISIN: DE000A37FT41 · WKN: A37FT4 · Symbol: ECX
1,6450
EUR
+1,23 %
+0,0200 EUR
Letzter Kurs 22.05.24 Tradegate
Neuigkeiten
TitelBeiträge |
---|
30.04.24 · wO Newsflash |
30.04.24 · EQS Group AG |
14.03.24 · wO Newsflash |
14.03.24 · wO Newsflash |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,2740 | +53,31 | |
1,0800 | +28,56 | |
2,1800 | +27,49 | |
1,9900 | +20,61 | |
10.777,50 | +19,75 |
Wertpapier | Kurs | Perf. % |
---|---|---|
46,20 | -16,00 | |
0,5701 | -16,77 | |
2,5100 | -17,43 | |
2,2001 | -20,57 | |
0,5920 | -38,33 |
Beitrag zu dieser Diskussion schreiben
Order zur KE komplett gestrichen...
Gut, dass das vor der KE kam...
Antwort auf Beitrag Nr.: 66.514.166 von cloud2017 am 19.01.21 22:48:07von niemanden wahrgenommen...noch
Morgen früh um 1€
Mich wundert das der Kurs noch bei über 3,xx Euro steht...
Das ist der Genickbruch für das Unternehmen. Tut mir echt Leid für alle Investierten.
Game Over...das war die endgültige Entscheidung und zwar VOR der KE.
Geldbeschaffung wirds so nicht mehr geben...ober wieder ein Kaptalschnitt von 10:1
Geldbeschaffung wirds so nicht mehr geben...ober wieder ein Kaptalschnitt von 10:1
Decision Summary
The Centers for Medicare & Medicaid Services (CMS) has determined that the evidence is sufficient to cover a blood-based biomarker test as an appropriate colorectal cancer screening test once every 3 years for Medicare beneficiaries when performed in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory, when ordered by a treating physician and when all of the following requirements are met:
The patient is:
* age 50-85 years, and,
* asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test or fecal immunochemical test), and,
* at average risk of developing colorectal cancer (no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease, including Crohn’s Disease and ulcerative colitis; no family history of colorectal cancers or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer).
The blood-based biomarker screening test must have all of the following:
* FDA market authorization with an indication for colorectal cancer screening; and
* proven test performance characteristics for a blood-based screening test with both sensitivity greater than or equal to 74% and specificity greater than or equal to 90% in the detection of colorectal cancer compared to the recognized standard (accepted as colonoscopy at this time), based on the pivotal studies included in the FDA labeling.
The currently available Epi proColon® test does not meet the criteria for an appropriate blood-based biomarker CRC screening test. Based on the evidence at this time, we will non-cover the Epi proColon® test.
The Centers for Medicare & Medicaid Services (CMS) has determined that the evidence is sufficient to cover a blood-based biomarker test as an appropriate colorectal cancer screening test once every 3 years for Medicare beneficiaries when performed in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory, when ordered by a treating physician and when all of the following requirements are met:
The patient is:
* age 50-85 years, and,
* asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test or fecal immunochemical test), and,
* at average risk of developing colorectal cancer (no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease, including Crohn’s Disease and ulcerative colitis; no family history of colorectal cancers or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer).
The blood-based biomarker screening test must have all of the following:
* FDA market authorization with an indication for colorectal cancer screening; and
* proven test performance characteristics for a blood-based screening test with both sensitivity greater than or equal to 74% and specificity greater than or equal to 90% in the detection of colorectal cancer compared to the recognized standard (accepted as colonoscopy at this time), based on the pivotal studies included in the FDA labeling.
The currently available Epi proColon® test does not meet the criteria for an appropriate blood-based biomarker CRC screening test. Based on the evidence at this time, we will non-cover the Epi proColon® test.
Antwort auf Beitrag Nr.: 66.511.046 von Rooobert am 19.01.21 19:46:21
Du hast schon mitbekommen das man ein Aktienbezug zu 1,10€ hat. Jetzt darfst dir den Rest selber denken.
Zitat von Rooobert: Der Kurs fällt und fällt. Was sagen die Schlaumeier dazu?
Du hast schon mitbekommen das man ein Aktienbezug zu 1,10€ hat. Jetzt darfst dir den Rest selber denken.
30.04.24 · wO Newsflash · Epigenomics |
30.04.24 · EQS Group AG · Epigenomics |
30.04.24 · EQS Group AG · Epigenomics |
14.03.24 · wO Newsflash · Epigenomics |
14.03.24 · wO Newsflash · Epigenomics |
14.03.24 · EQS Group AG · Epigenomics |
14.03.24 · EQS Group AG · Epigenomics |
15.02.24 · EQS Group AG · Epigenomics |
15.02.24 · EQS Group AG · Epigenomics |
31.01.24 · EQS Group AG · Epigenomics |